Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pegtarviliase - Spyre Therapeutics

Next Previous
Drug Profile

Pegtarviliase - Spyre Therapeutics

Alternative Names: ACN00177; AEB 4104; AEB-4104 program; AGLE-177

Latest Information Update: 26 Dec 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Aeglea Biotherapeutics
  • Developer Spyre Therapeutics
  • Class Enzymes; Recombinant proteins
  • Mechanism of Action Enzyme replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Homocystinuria
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Homocystinuria

Most Recent Events

  • 21 Apr 2023 Aeglea Biotherapeutics terminates a phase I/II trial in Homocystinuria (In adolescents, In adults, In the elderly) in United Kingdom, Australia, USA (SC/IV) due to sponsor's decision (NCT05154890)
  • 12 Apr 2023 Interim efficacy, adverse events and immunogenicity data from a phase I/II trial in Homocystinuria released by Aeglea Biotherapeutics
  • 02 Mar 2023 Pegtarviliase - Aeglea Biotherapeutics receives Fast Track designation for Homocystinuria [SC,Injection] (In adolescents, In the elderly, In adults) in USA, prior to March 2023

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top